Insider · CIK 0001383731
Michael F MacLean
Files at RNA (Avidity Biosciences, Inc.), CAMP (Camp4 Therapeutics Corp), VERV (Verve Therapeutics, Inc.). First filing Jan 23, 2024, latest Jan 23, 2026.
In brief
Michael F MacLean files SEC Form 4 as CFO and director at RNA (Avidity Biosciences, Inc.), and also at CAMP (Camp4 Therapeutics Corp), VERV (Verve Therapeutics, Inc.). Since Jan 23, 2024, Michael F MacLean has reported 0 open-market buys worth $0 and 9 open-market sells worth $8.3M, the latest filed on Jan 23, 2026.
A track record needs three past buys with six months of prices behind them; Michael F MacLean has 0, so none is measured yet.
The newest scored trade: sold $329k of RNA on Jan 21, 2026, filed Jan 23, 2026, scored 32 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $472k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RNA: Avidity Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Avidity Biosciences, Inc. | $329k 4,542 shares | -7% | - | |
| 28Weak | Avidity Biosciences, Inc. | $143k 1,974 shares | -3% | - | |
| 52Moderate | Avidity Biosciences, Inc. | $1.3M 30,914 shares | -32% | - | |
| 30Weak | Avidity Biosciences, Inc. | $246k 7,935 shares | -8% | - | |
| 27Weak | Avidity Biosciences, Inc. | $94k 3,287 shares | -3% | - | |
| 37Weak | Avidity Biosciences, Inc. | $364k 11,151 shares | -12% | - | |
| 47Moderate | Avidity Biosciences, Inc. | $4.8M 106,319 shares | -88% | - | |
| 37Weak | Avidity Biosciences, Inc. | $981k 40,000 shares | -48% | - | |
| 17Weak | Avidity Biosciences, Inc. | $16k 1,616 shares | -9% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | 30,914 0.03% of outstanding | $1.2M | Aug 6, 2025 | none |
| Nov 6, 2024 | RNA AVIDITY BIOSCIENCES INC | 106,319 0.10% of outstanding | $4.8M | Nov 6, 2024 | none |
| Mar 13, 2024 | RNA AVIDITY BIOSCIENCES INC | 40,000 0.05% of outstanding | $908k | Mar 13, 2024 | none |
Transactions
Every row this insider has filed, 34 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | CAMP Camp4 Therapeutics Corp | AGrant or award Stock Option (Right to Buy)derivative | +56,000 | $0.00 | $0 | 56,000 | Apr 3, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Common Stock | -133,977 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -92,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -131,250 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -148,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -60,125 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -106,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | - | - | 0 | Feb 27, 2026 |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -1,807 | $72.45 | $131k | 62,025 | Jan 23, 2026 |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -2,735 | $72.45 | $198k | 59,290 | Jan 23, 2026 |
| Jan 7, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -1,974 | $72.23 | $143k | 63,832 | Jan 9, 2026 |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -30,914 | $42.73 | $1.3M | 65,806 | Aug 15, 2025 |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -136,139 | - | - | 0 | Jul 28, 2025 |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -42,200 | - | - | 0 | Jul 28, 2025 |
| Jun 5, 2025 | VERV Verve Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +42,200 | $0.00 | $0 | 42,200 | Jun 6, 2025 |
| Mar 20, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -7,935 | $31.06 | $246k | 96,720 | Mar 21, 2025 |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -1,622 | $28.59 | $46k | 106,320 | Jan 23, 2025 |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -1,665 | $28.59 | $48k | 104,655 | Jan 23, 2025 |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 107,942 | Jan 8, 2025 |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 8, 2025 |
| Dec 18, 2024 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -11,151 | $32.66 | $364k | 82,942 | Dec 19, 2024 |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -27,262 | $46.22 | $1.3M | 94,093 | Nov 8, 2024 |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +65,182 | $8.82 | $575k | 159,275 | Nov 8, 2024 |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -65,182 | $45.33 | $3.0M | 94,093 | Nov 8, 2024 |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +13,875 | $6.57 | $91k | 107,968 | Nov 8, 2024 |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -13,875 | $45.33 | $629k | 94,093 | Nov 8, 2024 |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -65,182 | $0.00 | $0 | 0 | Nov 8, 2024 |
| Nov 6, 2024 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -13,875 | $0.00 | $0 | 60,125 | Nov 8, 2024 |
| Mar 13, 2024 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +40,000 | $8.82 | $353k | 84,093 | Mar 15, 2024 |
| Mar 13, 2024 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -40,000 | $24.52 | $981k | 44,093 | Mar 15, 2024 |
| Mar 13, 2024 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 244,427 | Mar 15, 2024 |
| Jan 20, 2024 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock10b5-1 | +22,500 | $0.00 | $0 | 27,209 | Jan 23, 2024 |
| Jan 22, 2024 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -1,616 | $10.13 | $16k | 16,884 | Jan 23, 2024 |
| Jan 20, 2024 | RNA Avidity Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +106,000 | $0.00 | $0 | 106,000 | Jan 23, 2024 |
Questions about Michael F MacLean
Answered from the filings on this page, as of the latest one.
Is Michael F MacLean buying or selling?
In the last 12 months Michael F MacLean reported 0 open-market buys worth $0 and 2 open-market sells worth $472k on SEC Form 4; the latest was sold $329k of RNA on Jan 21, 2026. Grants, option exercises and tax withholding are not counted.
How did Michael F MacLean's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael F MacLean has 0.
Where does Michael F MacLean file Form 4?
Michael F MacLean has filed Form 4 at RNA (Avidity Biosciences, Inc.) as Chief Financial Officer; CAMP (Camp4 Therapeutics Corp); VERV (Verve Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.